116 related articles for article (PubMed ID: 38342496)
21. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
22. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
23. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
24. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price EW; Zeglis BM; Cawthray JF; Ramogida CF; Ramos N; Lewis JS; Adam MJ; Orvig C
J Am Chem Soc; 2013 Aug; 135(34):12707-21. PubMed ID: 23901833
[TBL] [Abstract][Full Text] [Related]
25. Formulation of patient dose of ¹⁷⁷Lu-DOTA-TATE in hospital radiopharmacy in India: preparation using in situ methodology vis-a-vis freeze-dried kit.
Das T; Banerjee S
Cancer Biother Radiopharm; 2014 Sep; 29(7):301-2. PubMed ID: 25203147
[No Abstract] [Full Text] [Related]
26. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
27. Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.
Das T; Chakraborty S; Kallur KG; Venkatesh M; Banerjee S
Cancer Biother Radiopharm; 2011 Jun; 26(3):395-400. PubMed ID: 21728843
[TBL] [Abstract][Full Text] [Related]
28. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
31. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
32. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy.
Kang CS; Sun X; Jia F; Song HA; Chen Y; Lewis M; Chong HS
Bioconjug Chem; 2012 Sep; 23(9):1775-82. PubMed ID: 22881720
[TBL] [Abstract][Full Text] [Related]
34. A "mix-and-use" approach for formulation of human clinical doses of
Chakraborty S; Vimalnath KV; Rajeswari A; Chakravarty R; Sarma HD; Radhakrishnan E; Kamaleshwaran K; Shinto AS; Dash A
J Labelled Comp Radiopharm; 2017 Jul; 60(9):410-419. PubMed ID: 28477391
[TBL] [Abstract][Full Text] [Related]
35. Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy.
Chakraborty S; Vimalnath KV; Rajeswari A; Shinto A; Sarma HD; Kamaleshwaran K; Thirumalaisamy P; Dash A
J Labelled Comp Radiopharm; 2014 Jun; 57(7):453-62. PubMed ID: 24966157
[TBL] [Abstract][Full Text] [Related]
36. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
[TBL] [Abstract][Full Text] [Related]
37. In vivo and in vitro evaluation of
Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of new GnRH-I receptor radionuclide therapy with
Zoghi M; Attar Nosrati S; Rogni F; Shirvani G; Johari Daha F
J Labelled Comp Radiopharm; 2019 Jun; 62(7):310-320. PubMed ID: 31033025
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and comparative evaluation of
Sharma AK; Sharma R; Vats K; Sarma HD; Mukherjee A; Das T; Satpati D
Sci Rep; 2022 Sep; 12(1):15720. PubMed ID: 36127494
[TBL] [Abstract][Full Text] [Related]
40. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
Yook S; Lu Y; Jeong JJ; Cai Z; Tong L; Alwarda R; Pignol JP; Winnik MA; Reilly RM
Biomacromolecules; 2016 Apr; 17(4):1292-302. PubMed ID: 26974228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
